拓新藥業(301089.SZ)IPO擬公開發行3150萬股 10月12日初步詢價
格隆匯9月29日丨拓新藥業(301089.SZ)發佈首次公開發行股票並在創業板上市初步詢價及推介公吿,擬公開發行股票為3150萬股,佔發行後公司總股本的25%,全部為公開發行新股,此次發行不安排老股轉讓。此次公開發行後公司總股本為12600萬股。
此次發行的初始戰略配售發行數量為472.5萬股,佔此次發行總數量的15%。其中,發行人高管核心員工專項資產管理計劃參與戰略配售的數量為不超過此次公開發行數量的10%,即不超過315萬股,且認購金額不超過4723萬元;保薦機構相關子公司跟投數量預計為不超過此次公開發行數量的5%(如此次發行價格超過剔除最高報價後網下投資者報價的中位數和加權平均數以及剔除最高報價後公募基金、社保基金、養老金、企業年金基金和保險資金報價中位數、加權平均數孰低值,保薦機構相關子公司將按照相關規定參與此次發行的戰略配售),即不超過157.5萬股。戰略投資者最終配售數量與初始配售數量的差額將根據“六、本次發行回撥機制”規定的原則進行回撥。
回撥機制啟動前,網下初始發行數量為1874.25萬股,佔扣除初步戰略配售數量後發行數量的70%;網上初始發行數量為803.25萬股,佔扣除初步戰略配售數量後發行數量的30%。
最終網下、網上發行合計數量為此次發行總數量扣除最終戰略配售數量,網上及網下最終發行數量將根據回撥情況確定。最終網下、網上發行數量及戰略配售情況將在2021年10月20日(T+2日)刊登的《網下初步配售結果公吿》中予以明確。網下和網上投資者在申購時無需繳付申購資金。
此次發行的初步詢價時間為2021年10月12日(T-4日)9:30-15:00。在上述時間內,符合條件的網下投資者可通過網下發行電子平台填寫、提交擬申購價格和擬申購數量。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.